Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial *

ABSTRACT: Background. Hemodialysis (HD) patients with functional iron deficiency (FID) often develop resistance to recombinant human erythropoietin (rHuEpo). In these patients, iron therapy may be a hazard, leading to iron overload and consequently to hemosiderosis. Recent studies suggest that intravenous ascorbic acid (IVAA) may circumvent rHuEpo resistance. The aim of our study was to show the effects of IVAA on FID and whether this results in a better correction of anemia in HD patients with stable hemoglobin (Hb) concentration and FID.

Methods. Twenty-seven HD patients with serum ferritin > 300 µg/l, transferrin saturation (TS) < 20 % and hemoglobin (Hb) < 10 g/dL were selected and randomly divided into two groups to enter a cross-over trial with IVAA. In group I IV vitamin C 500 mg was administered three times a week for three months and discontinued in the next three months of the study. Vitamin C was not given the first three months in group II (control group, first three months of the study), who then received 500 mg IV three times a week for the next three months.
Results. Hb and TS% significantly increased (baselines vs 3 months, Hb 9.2 ± 0.2 vs 10.0 ± 0.3 g/dL, TS% 17.5 ± 0.6 vs 25.7 ± 1.7, respectively p < 0.01 and p <0.001) in group I after three months; ferritin fell significantly from 572 ± 40 to 398 ± 55 µg/L (p<0.004). Ten patients completed the study: mean Hb and TS% fell significantly (3 months vs final, Hb 9.9 ± 0.3 vs 8.9 ± 0.2 g/dL, TS% 25.1 ± 1.2 vs 19.1 ± 1.1, respectively p < 0.01 and p <0.001), while mean ferritin did not change. Mean Hb, ferritin and TS% remained unchanged in group II after three months. Hb and TS% mean values rose significantly (3 months vs final, Hb 9.0 ± 0.2 vs 9.9 ± 0.2 g/dl, TS% 18.4 ± 1.0 vs 27.0 ± 1.0, respectively p < 0.005 and p <0.001), and ferritin markedly decreased from 450 ± 50 to 206 ± 24 µg/L (p < 0.001) at the end of the study. The rHuEpo dose was kept unchanged throughout the study. Differences were analyzed after three months. Mean Hb rose (0.8 ± 0.2 g/dL) in group I but dropped (- 0.1 ± 0.1 g/dL) (p< 0.009) in group II. Ferritin dropped in both groups (group I vs group II, – 173 ± 48 vs – 33 ± 21 µg/L) (p < 0.01) while TS% increased (group I vs group II, 8.2 ± 1.5 vs 0.4 ± 0.7) (p < 0.001).

* Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

Published on 05-26-2008